News Releases

RNS Number : 3079D MaxCyte, Inc. 06 September 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , September 6, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Sep 06, 2024
RNS Number : 1550D MaxCyte, Inc. 06 September 2024   MaxCyte to Participate in Virtual Craig-Hallum Capital Group Bioprocessing Conference Rockville, MD , September 6, 2024 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Sep 06, 2024
RNS Number : 7585C MaxCyte, Inc. 03 September 2024   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights   ROCKVILLE, MD , September 3, 2024 :   MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance
Sep 03, 2024
RNS Number : 1597C MaxCyte, Inc. 29 August 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , August 29, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Aug 29, 2024
RNS Number : 4316Z MaxCyte, Inc. 07 August 2024   MaxCyte announces filing of Form 10-Q for the quarterly period ended June 30, 2024   ROCKVILLE, MD , August 7, 2024   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
Aug 07, 2024
RNS Number : 4498Z MaxCyte, Inc. 07 August 2024             MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates   Full Year 2024 Guidance   ROCKVILLE, MD , August 7, 2024   — MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing
Aug 07, 2024
RNS Number : 8744Y MaxCyte, Inc. 01 August 2024   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights   ROCKVILLE, MD , August 1, 2024 :   MaxCyte Inc. , (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
Aug 01, 2024
RNS Number : 4698Y MaxCyte, Inc. 31 July 2024     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , July 31, 2024 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
Jul 31, 2024